首页> 美国卫生研究院文献>Journal of Clinical Oncology >Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial

【2h】

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial

机译：辅助性他莫昔芬加卵巢功能抑制与单独使用他莫昔芬相比早期乳腺癌的绝经前妇女：患者报告的卵巢功能抑制试验结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeThe Suppression of Ovarian Function trial showed improved disease control for tamoxifen plus ovarian function suppression (OFS) compared with tamoxifen alone for the cohort of premenopausal patients who received prior chemotherapy. We present the patient-reported outcomes.

机译：目的抑制卵巢功能试验显示，对于接受过先前化疗的绝经前患者队列，与单独使用他莫昔芬相比，他莫昔芬加卵巢功能抑制（OFS）的疾病控制得到改善。我们介绍患者报告的结果。

著录项

期刊名称 Journal of Clinical Oncology
作者
Karin Ribi; Weixiu Luo; Jürg Bernhard; Prudence A. Francis; Harold J. Burstein; Eva Ciruelos; Meritxell Bellet; Lorenzo Pavesi; Ana Lluch; Marilena Visini; Vani Parmar; Carlo Tondini; Pierre Kerbrat; Antonia Perelló; Patrick Neven; Roberto Torres; Davide Lombardi; Fabio Puglisi; Per Karlsson; Thomas Ruhstaller; Marco Colleoni; Alan S. Coates; Aron Goldhirsch; Karen N. Price; Richard D. Gelber; Meredith M. Regan; Gini F. Fleming;
展开▼
作者单位

展开▼
年(卷),期 -1(34),14
年度 -1
页码 1601–1610
总页数 22
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial [J] . Ribi Karin, Luo Weixiu, Bernhard Jurg, Journal of Clinical Oncology . 2016,第14期

机译：在早期乳腺癌的绝经前妇女中，辅助用药他莫昔芬加卵巢功能抑制与单独使用他莫昔芬相比：患者报告的抑制卵巢功能试验的结果
2. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials [J] . Bernhard Juerg, Luo Weixiu, Ribi Karin, The lancet oncology . 2015,第7期

机译：患者报告的依西美坦与他莫昔芬辅助治疗在患有卵巢抑制的绝经前早期乳腺癌患者中的疗效（TEXT和SOFT）：两项3期随机试验的综合分析
3. Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of?published randomized controlled trials [J] . Shunchao Yan, Kai Li, Xin Jiao, OncoTargets and therapy . 2015,第3期

机译：他莫昔芬与卵巢癌的抑制作用相比单用他莫昔芬作为绝经前乳腺癌的辅助治疗：一项已发表的随机对照试验的荟萃分析
4. Study on the Efficacy Evaluation of Oral Sequential Tamoxifen in Postmenopausal Women with Hormone-dependent Breast Cancer [C] . Na Li, Yahua Sun, Sheng Zhao, International Conference on Life Sciences, Medicine, and Health . 2018

机译：激素依赖性乳腺癌后代妇女口腔序列儿毒素疗效评价研究
5. Dietary associations with biomarkers of breast cancer risk in women on adjuvant tamoxifen therapy. [D] . Strom, Meghan Brianna. 2016

机译：辅助性他莫昔芬治疗妇女饮食中与乳腺癌风险生物标志物的关联。
6. Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trials [O] . Jürg Bernhard, Weixiu Luo, Karin Ribi, -1

机译：依西美坦与他莫昔芬的辅助治疗在患有卵巢抑制的绝经前早期乳腺癌患者中：TEXT和SOFT随机试验中患者报告的结果
7. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial [O] . Ribi, Karin, Luo, Weixiu, Parmar, Vani, 2016

机译：在早期乳腺癌的绝经前妇女中，他莫昔芬联合卵巢功能抑制与单独使用他莫昔芬相比：患者报告的卵巢功能抑制试验结果

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial

摘要

著录项

相似文献

相关主题

期刊订阅